Media Mentions
2009
Jeffrey Jung and John Tamisiea examined the increasing use of royalty financing techniques with respect to pharmaceutical and biotech assets as a source of capital in their article that appeared in The Deal Magazine on June 15. “As more market participants use royalty financing techniques as an alternative financing tool, and as the transactions continue to increase in size, there is likely to be a corresponding continued increase in transactional complexity,” the authors stated. Such transactions include investments in the anticipated future revenues from late development stage or precommercial launch products (“revenue interest” or “synthetic royalty” transactions), and various hybrid financing structures.
Jeffrey A. Jung, John P. Tamisiea, Corporate, Health, Healthcare Royalty Sales
